Biogen | BIIB - Trade Debtors


Biogen reported $1.85B in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
ALKERMES USD 334.02M 21.08M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Bayer EUR 14.91B 2.73B Sep/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Esperion Therapeutics USD 60.36M 5.75M Jun/2024
Gilead Sciences USD 4.91B 182M Dec/2025
Incyte USD 1.02B 128.52M Dec/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 184M 862M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 397M 100M Dec/2025
Sanofi EUR 397M 186.13M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Teva Pharmaceutical Industries USD 3.71B 101M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
United Therapeutics USD 350.2M 52.5M Dec/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025